×
About 1,295 results

ALLMedicine™ Invasive Lobular Carcinoma Center

Research & Reviews  631 results

HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison ...
https://doi.org/10.3390/curroncol28030150
Current Oncology (Toronto, Ont.); He L, Araj E et. al.

Apr 30th, 2021 - Human epidermal growth factor receptor 2 (HER2) positive (+) classical type invasive lobular carcinoma (cILC) of the breast is extremely rare and its clinicopathologic features have not been well characterized. We compared features of HER2(+) and ...

A 58-Year-Old Woman with Acute Gastric Perforation Due to Metastatic Ductal Carcinoma 1...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042419
The American Journal of Case Reports; Nehmeh WA, Derienne J et. al.

Apr 8th, 2021 - BACKGROUND Invasive lobular carcinoma and ductal carcinoma of the breast can metastasize to all sites in the body, including the gastrointestinal tract. Late presentation of metastases of lobular carcinoma of the breast to the gastrointestinal tra...

Rapid Assessment of Resection Margins During Breast Conserving Surgery Using Intraopera...
https://doi.org/10.1016/j.clbc.2021.03.002
Clinical Breast Cancer; Vartholomatos G, Ηarissis Η et. al.

Apr 6th, 2021 - Positive margins are the most important factor for recurrence of the disease after breast-conserving surgery. Several methods have been developed throughout the years to evaluate the margin status during surgery in an attempt to assist the surgeon...

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with sp...
https://doi.org/10.1038/s41379-021-00742-9 10.2217/14796694.5.2.233 10.1186/s13058-015-0519-x 10.1016/j.cell.2015.09.033 10.1097/00000658-199522240-00012 10.1186/bcr767 10.1016/j.ejca.2007.10.009 10.1200/JCO.2007.14.9336 10.1038/modpathol.2009.145 10.1158/1078-0432.CCR-06-3045 10.1172/JCI45014 10.1016/j.ccell.2019.02.001 10.1158/1078-0432.CCR-14-0432 10.1002/path.1559 10.1007/s00428-003-0859-2 10.3349/ymj.2011.52.1.89 10.1016/j.clbc.2012.09.002 10.1097/PAI.0b013e3182a5a02d 10.1007/s10549-012-2002-z 10.1111/j.1365-2559.1991.tb00229.x 10.5858/arpa.2018-0902-SA 10.1111/his.12869 10.1097/PAS.0b013e318158d6c5 10.1038/s41416-019-0420-y 10.1038/s41379-018-0047-1 10.1186/s13059-016-0974-4 10.1016/S0140-6736(16)32454-0 10.1016/j.semcancer.2017.03.007 10.1038/nbt.3519 10.1186/s13059-014-0550-8 10.1200/JCO.2008.18.1370 10.4137/CIN.S9983 10.1016/j.jsbmb.2008.12.005 10.1016/j.ejca.2018.04.011 10.1158/1078-0432.CCR-13-0583 10.1056/NEJMoa1809615 10.1038/s41523-019-0109-7 10.1002/ijc.23518 10.1158/1078-0432.CCR-04-0220 10.1016/j.humpath.2012.09.005 10.1016/j.jsbmb.2012.08.007 10.1038/emboj.2011.216 10.1038/nrc3396 10.1158/0008-5472.CAN-09-1251 10.1093/nar/gkn520 10.1158/1078-0432.CCR-15-0857 10.1016/j.ctrv.2018.06.005 10.1093/annonc/mdw067
Modern Pathology : an Official Journal of the United Stat... Bergeron A, MacGrogan G et. al.

Mar 23rd, 2021 - Primary triple-negative invasive lobular breast carcinomas (TN-ILCs), which do not express hormone receptors and HER2 at diagnosis, are rare and poorly known. In this study, we analyzed the largest TN-ILC series ever reported in the literature, in...

Extrapolation of ACOSOG Z0011 trial results-A survey of breast cancer providers.
https://doi.org/10.1111/tbj.14226
The Breast Journal; Weiss A, Cooley V et. al.

Mar 15th, 2021 - We surveyed breast providers from a national oncology cooperative group to evaluate axillary management recommendations for patients with 1-2 positive sentinel lymph nodes (+SLNs) with scenarios not explicitly included in the Z0011 trial. These sc...

see more →

Clinicaltrials.gov  653 results

HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison ...
https://doi.org/10.3390/curroncol28030150
Current Oncology (Toronto, Ont.); He L, Araj E et. al.

Apr 30th, 2021 - Human epidermal growth factor receptor 2 (HER2) positive (+) classical type invasive lobular carcinoma (cILC) of the breast is extremely rare and its clinicopathologic features have not been well characterized. We compared features of HER2(+) and ...

A 58-Year-Old Woman with Acute Gastric Perforation Due to Metastatic Ductal Carcinoma 1...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042419
The American Journal of Case Reports; Nehmeh WA, Derienne J et. al.

Apr 8th, 2021 - BACKGROUND Invasive lobular carcinoma and ductal carcinoma of the breast can metastasize to all sites in the body, including the gastrointestinal tract. Late presentation of metastases of lobular carcinoma of the breast to the gastrointestinal tra...

Rapid Assessment of Resection Margins During Breast Conserving Surgery Using Intraopera...
https://doi.org/10.1016/j.clbc.2021.03.002
Clinical Breast Cancer; Vartholomatos G, Ηarissis Η et. al.

Apr 6th, 2021 - Positive margins are the most important factor for recurrence of the disease after breast-conserving surgery. Several methods have been developed throughout the years to evaluate the margin status during surgery in an attempt to assist the surgeon...

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with sp...
https://doi.org/10.1038/s41379-021-00742-9 10.2217/14796694.5.2.233 10.1186/s13058-015-0519-x 10.1016/j.cell.2015.09.033 10.1097/00000658-199522240-00012 10.1186/bcr767 10.1016/j.ejca.2007.10.009 10.1200/JCO.2007.14.9336 10.1038/modpathol.2009.145 10.1158/1078-0432.CCR-06-3045 10.1172/JCI45014 10.1016/j.ccell.2019.02.001 10.1158/1078-0432.CCR-14-0432 10.1002/path.1559 10.1007/s00428-003-0859-2 10.3349/ymj.2011.52.1.89 10.1016/j.clbc.2012.09.002 10.1097/PAI.0b013e3182a5a02d 10.1007/s10549-012-2002-z 10.1111/j.1365-2559.1991.tb00229.x 10.5858/arpa.2018-0902-SA 10.1111/his.12869 10.1097/PAS.0b013e318158d6c5 10.1038/s41416-019-0420-y 10.1038/s41379-018-0047-1 10.1186/s13059-016-0974-4 10.1016/S0140-6736(16)32454-0 10.1016/j.semcancer.2017.03.007 10.1038/nbt.3519 10.1186/s13059-014-0550-8 10.1200/JCO.2008.18.1370 10.4137/CIN.S9983 10.1016/j.jsbmb.2008.12.005 10.1016/j.ejca.2018.04.011 10.1158/1078-0432.CCR-13-0583 10.1056/NEJMoa1809615 10.1038/s41523-019-0109-7 10.1002/ijc.23518 10.1158/1078-0432.CCR-04-0220 10.1016/j.humpath.2012.09.005 10.1016/j.jsbmb.2012.08.007 10.1038/emboj.2011.216 10.1038/nrc3396 10.1158/0008-5472.CAN-09-1251 10.1093/nar/gkn520 10.1158/1078-0432.CCR-15-0857 10.1016/j.ctrv.2018.06.005 10.1093/annonc/mdw067
Modern Pathology : an Official Journal of the United Stat... Bergeron A, MacGrogan G et. al.

Mar 23rd, 2021 - Primary triple-negative invasive lobular breast carcinomas (TN-ILCs), which do not express hormone receptors and HER2 at diagnosis, are rare and poorly known. In this study, we analyzed the largest TN-ILC series ever reported in the literature, in...

Extrapolation of ACOSOG Z0011 trial results-A survey of breast cancer providers.
https://doi.org/10.1111/tbj.14226
The Breast Journal; Weiss A, Cooley V et. al.

Mar 15th, 2021 - We surveyed breast providers from a national oncology cooperative group to evaluate axillary management recommendations for patients with 1-2 positive sentinel lymph nodes (+SLNs) with scenarios not explicitly included in the Z0011 trial. These sc...

see more →

News  7 results

Genetic Test Spots High-Risk Invasive Lobular Carcinoma
https://www.staging.medscape.com/viewarticle/938558

Oct 5th, 2020 - NEW YORK (Reuters Health) - A test that looks at the activity of 70 genes in breast tumors can help identify women with invasive lobular carcinoma (ILC) at high-risk of cancer recurrence or progression after surgery who may benefit from additional...

Genetic Test Spots High-Risk Invasive Lobular Carcinoma
https://www.medscape.com/viewarticle/938558

Oct 5th, 2020 - NEW YORK (Reuters Health) - A test that looks at the activity of 70 genes in breast tumors can help identify women with invasive lobular carcinoma (ILC) at high-risk of cancer recurrence or progression after surgery who may benefit from additional...

Distinct Strategies Needed for Treating Lobular Breast Cancer
https://www.onclive.com/publications/oncology-live/2015/may-2015/distinct-strategies-needed-for-treating-lobular-breast-cancer

Apr 28th, 2015 - Jennifer Yuchen Shih, MD, MS Although patients with invasive lobular carcinoma (ILC) are typically treated with the same therapeutic strategies as those with infiltrating ductal malignancies, ILC is emerging as a molecularly complex and distinct t...

Guidelines: No ink on tumor is adequate surgical margin for early-stage breast cancer
https://www.mdedge.com/hematology-oncology/article/80349/breast-cancer/guidelines-no-ink-tumor-adequate-surgical-margin/page/0/1

Feb 12th, 2014 - In additional findings, there was no evidence that wider margins beyond no ink on tumor are indicated in patients having more aggressive biological subtypes of breast cancer, invasive lobular carcinoma, or tumors with an extensive intraductal comp.

Long-term CCB therapy linked to higher breast cancer risk
https://www.mdedge.com/internalmedicine/article/76950/hypertension/long-term-ccb-therapy-linked-higher-breast-cancer-risk
Mary Ann Moon

Aug 5th, 2013 - The long-term use of calcium-channel blockers is associated with a doubling of the risk of both invasive ductal carcinoma and invasive lobular carcinoma of the breast, according to a report published online Aug. 5 in JAMA Internal Medicine.

see more →

Patient Education  4 results see all →